Sinusoidal obstruction syndrome

Clinics and Research in Hepatology and Gastroenterology

Volumn 40, Issue 4, 2016, Pages 378-385

  Valla, Dominique Charles ^a,b,c   Cazals Hatem, Dominique ^a,b,c  

^a Service d Hépatologie   (France)

^b BEAUJON HOSPITAL   (France)

^c CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; CYCLOPHOSPHAMIDE; HEPARIN; OXALIPLATIN; PYRROLIZIDINE ALKALOID; TISSUE PLASMINOGEN ACTIVATOR; URSODEOXYCHOLIC ACID; ANTINEOPLASTIC AGENT;

COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; GENETIC POLYMORPHISM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CONGESTION; LIVER INJURY; LIVER METASTASIS; LIVER VENOOCCLUSIVE DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SHORT SURVEY; LIVER TUMOR; LIVER VEIN OBSTRUCTION;

ANTINEOPLASTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; LIVER NEOPLASMS; PYRROLIZIDINE ALKALOIDS;

EID: 84962081916     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2016.01.006     Document Type: Short Survey

References (55)

1. [1] Stuart, K.L., Bras, G., Veno-occlusive disease of the liver. QJM 26 (1957), 291–315.
2. [2] Brooks, S.E., Miller, C.G., McKenzie, K., Audretsch, J.J., Bras, G., Acute veno-occlusive disease of the liver. Fine structure in Jamaican children. Arch Pathol 89 (1970), 507–520.
3. [3] Edgar, J.A., Molyneux, R.J., Colegate, S.M., Pyrrolizidine alkaloids: potential role in the etiology of cancers, pulmonary hypertension, congenital anomalies, and liver disease. Chem Res Toxicol 28 (2015), 4–20.
4. [4] Tandon, R.K., Tandon, B.N., Tandon, H.D., Bhatia, M.L., Bhargava, S., Lal, P., et al. Study of an epidemic of venoocclusive disease in India. Gut 17 (1976), 849–855.
5. [5] Lin, G., Wang, J.Y., Li, N., Li, M., Gao, H., Ji, Y., et al. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol 54 (2011), 666–673.
6. [6] Edgar, J.A., Roeder, E., Molyneux, R.J., Honey from plants containing pyrrolizidine alkaloids: a potential threat to health. J Agric Food Chem 50 (2002), 2719–2730.
7. [7] Robinson, O., Want, E., Coen, M., Kennedy, R., van den Bosch, C., Gebrehawaria, Y., et al. Hirmi Valley liver disease: a disease associated with exposure to pyrrolizidine alkaloids and DDT. J Hepatol 60 (2014), 96–102.
8. [8] DeLeve, L.D., McCuskey, R.S., Wang, X., Hu, L., McCuskey, M.K., Epstein, R.B., et al. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology 29 (1999), 1779–1791.
9. [9] Wang, X., Kanel, G.C., DeLeve, L.D., Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat. Hepatology 31 (2000), 428–434.
10. [10] Deleve, L.D., Wang, X., Tsai, J., Kanel, G., Strasberg, S., Tokes, Z.A., Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition. Gastroenterology 125 (2003), 882–890.
11. [11] DeLeve, L.D., Wang, X., Kanel, G.C., Ito, Y., Bethea, N.W., McCuskey, M.K., et al. Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome. Hepatology 38 (2003), 900–908.
12. [12] Harb, R., Xie, G., Lutzko, C., Guo, Y., Wang, X., Hill, C.K., et al. Bone marrow progenitor cells repair rat hepatic sinusoidal endothelial cells after liver injury. Gastroenterology 137 (2009), 704–712.
13. [13] Shulman, H.M., McDonald, G.B., Matthews, D., Doney, K.C., Kopecky, K.J., Gauvreau, J.M., et al. An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology 79 (1980), 1178–1191.
14. [14] DeLeve, L.D., Valla, D.C., Garcia-Tsao, G., Vascular disorders of the liver. Hepatology 49 (2009), 1729–1764.
15. [15] Shulman, H.M., Gooley, T., Dudley, M.D., Kofler, T., Feldman, R., Dwyer, D., et al. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation 59 (1995), 1015–1022.
16. [16] Carreras, E., Granena, A., Navasa, M., Bruguera, M., Marco, V., Sierra, J., et al. Transjugular liver biopsy in BMT. Bone Marrow Transplant 11 (1993), 21–26.
17. [17] Azar, N., Valla, D., Abdel-Samad, I., Hoang, C., Fretz, C., Sutton, L., et al. Liver dysfunction in allogeneic bone marrow transplantation recipients. Transplantation 62 (1996), 56–61.
18. [18] Blostein, M.D., Paltiel, O.B., Thibault, A., Rybka, W.B., A comparison of clinical criteria for the diagnosis of veno-occlusive disease of the liver after bone marrow transplantation. Bone Marrow Transplant 10 (1992), 439–443.
19. [19] Carreras, E., Granena, A., Navasa, M., Bruguera, M., Marco, V., Sierra, J., et al. On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease. Ann Hematol 66 (1993), 77–80.
20. [20] Mahgerefteh, S.Y., Sosna, J., Bogot, N., Shapira, M.Y., Pappo, O., Bloom, A.I., Radiologic imaging and intervention for gastrointestinal and hepatic complications of hematopoietic stem cell transplantation. Radiology 258 (2011), 660–671.
21. [21] Carreras, E., Bertz, H., Arcese, W., Vernant, J.P., Tomas, J.F., Hagglund, H., et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 92 (1998), 3599–3604.
22. [22] DeLeve, L.D., Wang, X., Kuhlenkamp, J.F., Kaplowitz, N., Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease. Hepatology 23 (1996), 589–599.
23. [23] Dignan, F.L., Wynn, R.F., Hadzic, N., Karani, J., Quaglia, A., Pagliuca, A., et al. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol 163 (2013), 444–457.
24. [24] Zhang, L., Wang, Y., Huang, H., Defibrotide for the prevention of hepatic veno-occlusive disease after hematopoietic stem cell transplantation: a systematic review. Clin Transplant 26 (2012), 511–519.
25. [25] Corbacioglu, S., Cesaro, S., Faraci, M., Valteau-Couanet, D., Gruhn, B., Rovelli, A., et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 379 (2012), 1301–1309.
26. [26] Richardson, P.G., Corbacioglu, S., Ho, V.T., Kernan, N.A., Lehmann, L., Maguire, C., et al. Drug safety evaluation of defibrotide. Expert Opin Drug Saf 12 (2013), 123–136.
27. [27] Valla, D.C., Budd-Chiari syndrome and veno-occlusive disease/sinusoidal obstruction syndrome. Gut 57 (2008), 1469–1478.
28. [28] Van Cutsem, E., Cervantes, A., Nordlinger, B., Arnold, D., Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25:Suppl. 3 (2014), iii1–iii9.
29. [29] Vigano, L., Capussotti, L., De Rosa, G., De Saussure, W.O., Mentha, G., Rubbia-Brandt, L., Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg 258 (2013), 731–740 [discussion 741-732].
30. [30] Nguyen-Khac, E., Lobry, C., Chatelain, D., Fuks, D., Joly, J.P., Brevet, M., et al. A reappraisal of chemotherapy-induced liver injury in colorectal liver metastases before the era of antiangiogenics. Int J Hepatol, 2013, 2013, 314868.
31. [31] Rubbia-Brandt, L., Audard, V., Sartoretti, P., Roth, A.D., Brezault, C., Le Charpentier, M., et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15 (2004), 460–466.
32. [32] Rubbia-Brandt, L., Lauwers, G.Y., Wang, H., Majno, P.E., Tanabe, K., Zhu, A.X., et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 56 (2010), 430–439.
33. [33] Hubert, C., Sempoux, C., Humblet, Y., van den Eynde, M., Zech, F., Leclercq, I., et al. Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab. HPB (Oxford), 2013.
34. [34] Robinson, S.M., Wilson, C.H., Burt, A.D., Manas, D.M., White, S.A., Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol 19 (2012), 4287–4299.
35. [35] van der Pool, A.E., Marsman, H.A., Verheij, J., Ten Kate, F.J., Eggermont, A.M., Ijzermans, J.N., et al. Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases. J Surg Oncol 106 (2012), 892–897.
36. [36] Robinson, S.M., Mann, J., Vasilaki, A., Mathers, J., Burt, A.D., Oakley, F., et al. Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model. J Hepatol 59 (2013), 318–326.
37. [37] Rubbia-Brandt, L., Tauzin, S., Brezault, C., Delucinge-Vivier, C., Descombes, P., Dousset, B., et al. Gene expression profiling provides insights into pathways of oxaliplatin-related sinusoidal obstruction syndrome in humans. Mol Cancer Ther 10 (2011), 687–696.
38. [38] Agostini, J., Benoist, S., Seman, M., Julie, C., Imbeaud, S., Letourneur, F., et al. Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation. J Hepatol 56 (2012), 869–876.
39. [39] Robinson, S.M., Mann, D.A., Manas, D.M., Oakley, F., Mann, J., White, S.A., The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome. Br J Cancer 109 (2013), 2396–2403.
40. [40] Marzano, C., Cazals-Hatem, D., Rautou, P.E., Valla, D.C., The significance of nonobstructive sinusoidal dilatation of the liver: impaired portal perfusion or inflammatory reaction syndrome. Hepatology, 2015.
41. [41] Arotcarena, R., Cales, V., Berthelemy, P., Parent, Y., Malet, M., Etcharry, F., et al. Severe sinusoidal lesions: a serious and overlooked complication of oxaliplatin-containing chemotherapy?. Gastroenterol Clin Biol 30 (2006), 1313–1316.
42. [42] van Iersel, L.B., de Leede, E.M., Vahrmeijer, A.L., Tijl, F.G., den Hartigh, J., Kuppen, P.J., et al. Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study. Eur J Surg Oncol 40 (2014), 1557–1563.
43. [43] Lehmann, K., Rickenbacher, A., Weber, A., Pestalozzi, B.C., Clavien, P.A., Chemotherapy before liver resection of colorectal metastases: friend or foe?. Ann Surg 255 (2012), 237–247.
44. [44] Soubrane, O., Brouquet, A., Zalinski, S., Terris, B., Brezault, C., Mallet, V., et al. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann Surg 251 (2010), 454–460.
45. [45] Vreuls, C.P., Van Den Broek, M.A., Winstanley, A., Koek, G.H., Wisse, E., Dejong, C.H., et al. Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases. Histopathology 61 (2012), 314–318.
46. [46] Vreuls, C.P., Olde Damink, S.W., Koek, G.H., Winstanley, A., Wisse, E., Cloots, R.H., et al. Glutathione S-transferase M1-null genotype as risk factor for SOS in oxaliplatin-treated patients with metastatic colorectal cancer. Br J Cancer 108 (2013), 676–680.
47. [47] van den Broek, M.A., Vreuls, C.P., Winstanley, A., Jansen, R.L., van Bijnen, A.A., Dello, S.A., et al. Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases. Ann Surg Oncol 20 (2013), 1462–1469.
48. [48] Shin, N.Y., Kim, M.J., Lim, J.S., Park, M.S., Chung, Y.E., Choi, J.Y., et al. Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases. Eur Radiol 22 (2012), 864–871.
49. [49] Han, N.Y., Park, B.J., Sung, D.J., Kim, M.J., Cho, S.B., Lee, C.H., et al. Chemotherapy-induced focal hepatopathy in patients with gastrointestinal malignancy: gadoxetic acid—enhanced and diffusion-weighted MR imaging with clinical-pathologic correlation. Radiology 271 (2014), 416–425.
50. [50] Sebagh, M., Azoulay, D., Roche, B., Hoti, E., Karam, V., Teicher, E., et al. Significance of isolated hepatic veno-occlusive disease/sinusoidal obstruction syndrome after liver transplantation. Liver Transpl 17 (2011), 798–808.
51. [51] Takamura, H., Nakanuma, S., Hayashi, H., Tajima, H., Kakinoki, K., Kitahara, M., et al. Severe veno-occlusive disease/sinusoidal obstruction syndrome after deceased-donor and living-donor liver transplantation. Transplant Proc 46 (2014), 3523–3535.
52. [52] Wang, T., Ong, P., Roscioli, T., Cliffe, S.T., Church, J.A., Hepatic veno-occlusive disease with immunodeficiency (VODI): first reported case in the U.S. and identification of a unique mutation in Sp110. Clin Immunol 145 (2012), 102–107.
53. [53] Tallman, M.S., McDonald, G.B., DeLeve, L.D., Baer, M.R., Cook, M.N., Graepel, G.J., et al. Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practice. Int J Hematol 97 (2013), 456–464.
54. [54] Vion, A.C., Rautou, P.E., Durand, F., Boulanger, C.M., Valla, D.C., Interplay of inflammation and endothelial dysfunction in bone marrow transplantation: Focus on hepatic veno-occlusive disease. Semin Thromb Hemost, 2015.
55. [55] Snover, D.C., Weisdorf, S., Bloomer, J., McGlave, P., Weisdorf, D., Nodular regenerative hyperplasia of the liver following bone marrow transplantation. Hepatology 9 (1989), 443–448.